Controlling CRISPR with Small Molecule Regulation for Somatic Cell Genome Editing
Overview
Pharmacology
Authors
Affiliations
Biomedical research has been revolutionized by the introduction of many CRISPR-Cas systems that induce programmable edits to nearly any gene in the human genome. Nuclease-based CRISPR-Cas editors can produce on-target genomic changes but can also generate unwanted genotoxicity and adverse events, in part by cleaving non-targeted sites in the genome. Additional translational challenges for in vivo somatic cell editing include limited packaging capacity of viral vectors and host immune responses. Altogether, these challenges motivate recent efforts to control the expression and activity of different Cas systems in vivo. Current strategies utilize small molecules, light, magnetism, and temperature to conditionally control Cas systems through various activation, inhibition, or degradation mechanisms. This review focuses on small molecules that can be incorporated as regulatory switches to control Cas genome editors. Additional development of CRISPR-Cas-based therapeutic approaches with small molecule regulation have high potential to increase editing efficiency with less adverse effects for somatic cell genome editing strategies in vivo.
Chen J, Su S, Pickar-Oliver A, Chiarella A, Hahn Q, Goldfarb D Nucleic Acids Res. 2024; 52(19):11536-11551.
PMID: 39228373 PMC: 11514467. DOI: 10.1093/nar/gkae761.
MiRNA-Responsive CRISPR-Cas System via a DNA Regulator.
Yun D, Jung C Biosensors (Basel). 2023; 13(11).
PMID: 37998150 PMC: 10669420. DOI: 10.3390/bios13110975.
Singh M, Agarwal V, Jindal D, Pancham P, Agarwal S, Mani S Diagnostics (Basel). 2023; 13(3).
PMID: 36766442 PMC: 9914305. DOI: 10.3390/diagnostics13030337.
The CRISPR-Cas system as a tool for diagnosing and treating infectious diseases.
Lou J, Wang B, Li J, Ni P, Jin Y, Chen S Mol Biol Rep. 2022; 49(12):11301-11311.
PMID: 35857175 PMC: 9297709. DOI: 10.1007/s11033-022-07752-z.
Tailoring Cardiac Synthetic Transcriptional Modulation Towards Precision Medicine.
Schoger E, Lelek S, Panakova D, Zelarayan L Front Cardiovasc Med. 2022; 8:783072.
PMID: 35097003 PMC: 8795974. DOI: 10.3389/fcvm.2021.783072.